So I'm hoping you can set the scene for us and explain what that means and why it matters for patients, not just for industry.

Sure.

So thanks so much for mentioning this research, and I think it really highlights the rapidly evolving pace of how cancer drugs are being developed now, which is, I think, in two ways, both incredibly, um, exciting but also poses some real challenges.

So herding really refers to when multiple companies are looking and developing similar drugs at, um, similar targets for similar cancers.

And I think in some ways this is rational, and one can see that when there are exciting new ways to target cancer, for example, immunotherapy or using targeted drugs like the ones Beth, um, spoke of in lung cancer, it would therefore create an opportunity for multiple companies to develop drugs in that setting.

I think in the short term, in bringing this back to Beth's story, it's incredibly helpful having multiple drugs available because it then opens up access for patients.

And we really see in my day-to-day job, uh, in early phase clinical trials that patients need drugs urgently at the time when the standard of care treatment is no longer working, when they're still well enough to derive benefit from those treatments.

And so why is it happening?

I mean, what are the conversations you're having with occupiers? I think

these days the conversation has really shifted and It's moving away from, you know, should we have art to how do we use it in a way that actually really means something to the organization? And it usually comes back to three drivers, culture and identity, talent retraction and retention, and also the overall workplace experience and what we're trying to achieve.

because people want a place they genuinely actually choose to come to, not because, you know, it's a place they have to go to.

On return on investment, people ask all the time, you know, but you rarely measure art in a neat little box.

We look at a mix of engagement, utilisation, dwell time, you know, how long people are spending looking at the art, but also sentiment.

And I'd say art is a multiplier.

It can really lift the impact of great design, hospitality and technology.

Jenny, is art becoming standard in premium offices or will it remain a differentiator?

... what makes J-beauty so unique?

Yeah.

Japanese skincare, I think you guys kinda defined it, is that ritual aspect, right? But to me, it's not just, like, that self-care part of ritual, but also time and dedication.

J-beauty, I like to describe it as more simplicity, consistency for that long-term skin health, right? The fact that your skin quality and skin health is built over, like, decades, not overnight transformation.

And also, like you said, it's really that thought for formulation, like, using science-backed ingredients used through history, but really that unique formula that-... prioritizes the texture-

Yeah? [laughs]

Because, yes, you are right.

14 days, that is a pretty bold claim, right? But then I look at their studies.